Table 1 Threshold for respondents to initiate bevacizumab for HOCF based on clinical scenario. CO, cardiac output; CI, cardiac index; NT-proBNP, N-terminal pro-brain natriuretic peptide
Clinical Scenario | Would Initiate Bevacizumab | Would Not Initiate Bevacizumab |
|---|---|---|
Elevated CO/CI, normal NT-proBNP Moderate left atrial enlargement, no arrhythmias No signs or symptoms of HF or activity restriction | 11% | 89% |
Elevated CO/CI, elevated NT-proBNP Moderate left atrial enlargement, no arrhythmias No signs or symptoms of HF or activity restriction | 11% | 89% |
Elevated CO/CI, elevated NT-proBNP Severe left atrial enlargement, no arrhythmias No signs or symptoms of HF or activity restriction | 26% | 74% |
Elevated CO/CI, elevated NT-proBNP Severe left atrial enlargement, paroxysmal atrial fibrillation No signs or symptoms of HF or activity restriction | 63% | 37% |
Elevated CO/CI, elevated NT-proBNP Severe left atrial enlargement, paroxysmal atrial fibrillation Mild dyspnea on exertion, exercise limitation | 79% | 21% |